TD Cowen initiated coverage of Damora Therapeutics (NASDAQ: DMRA) with a Buy rating on June 8, 2026. The firm cited confidence in the biotechnology company’s clinical pipeline.
Analysts focused on lead asset DMR-001, a monoclonal antibody for rare blood disorders. The drug treats conditions including essential thrombocythemia and myelofibrosis.
Preclinical studies show significant potency for DMR-001 as a disease-modifying therapy. This initiation follows recent bullish calls from RBC Capital and Evercore ISI.
The consensus rating for Damora Therapeutics currently stands as a Strong Buy.